在质母细胞瘤中,GPRC5A通过糖溶性重编程来调节对temozolomide的耐药性
Wahafu Alafate1, Shichao Du2, Shiyue Pan1
1Department of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
International journal of biological macromolecules
|July 31, 2025
概括
多型质母细胞瘤 (GBM) 涉及上调的GPRC5A,促进化学抵抗和低生存率. 针对GPRC5A和GLUT1相互作用可能会改善质母细胞瘤治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症基因组学 癌症基因组学
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
- 对泰莫索洛米德 (TMZ) 等疗法的化学抗药性是GBM治疗中的一个主要挑战.
研究的目的:
- 调查G蛋白结合受体类C组5成员A (GPRC5A) 在GBM中的作用.
- 确定GPRC5A与泰莫索洛米德 (TMZ) 耐药性和患者结局的关联.
主要方法:
- 癌症治疗应对门户网站 (CTRP) 和癌症基因组图谱 (TCGA) 数据库的综合分析.
- 功能性检测包括瘤球体形成和干细胞标志物分析 (CD133).
- 对缺氧,葡萄糖代谢,HIF-1和糖溶性通路的生物信息分析;体内研究.
主要成果:
- 在GBM中,GPRC5A显著上调,与较差的生存率和TMZ耐药性相关.
- 过度表达GPRC5A促进了类似干细胞的特性,增强了瘤球体的形成.
- GPRC5A与GLUT1相互作用,调节葡萄糖吸收和糖解; GPRC5A沉默增加了TMZ的敏感性.
结论:
- GPRC5A在GBM的进展和化学抵抗中发挥着关键作用.
- 针对GPRC5A-GLUT1相互作用是一种潜在的治疗策略,以克服GBM中的TMZ耐药性.
- 抑制GPRC5A会减少瘤的生长,并改善体内生存率.
更多相关视频
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
5.7K
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.9K
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
